SV

Street Verdict

Analyst Scorecard

AJANTPHARM · NSE

Ajanta Pharma Limited

₹3,563.6

+1.80% (+₹63.1)

Prev. close

₹3,500.5

Volume

2,01,322

Delivery %

59.7%

As of

18 Sept 2026

Price history

₹3,563.6+₹488.7 (+15.89%) · 3M
10 Jun 2026 → 18 Sept 2026
₹3,718.2₹3,054.410 Jun03 Jul03 Aug26 Aug18 Sept
Daily closes · updates after each session

No analyst calls on this stock in the last 90 days yet.

Explore by date range →

Analyst opinions

No analyst calls on Ajanta Pharma Limited in the last 90 days.

Fundamentals

About Ajanta Pharma Limited

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Yogesh Mannalal Agrawal M.B.A

Headquarters

Mumbai

Employees

10,421

Key stats

Market cap

₹44,530.40 Cr

P/E ratio (TTM)

39.3

Dividend yield

1.83%

EPS (TTM)

₹90.66

Beta (1Y · daily vs NIFTY 50)

0.55

Beta (5Y · monthly vs NIFTY 50)

0.76

Shares float

4.20 Cr

EPS · quarter ended Jun 2026

₹26.72

Financial Performance

01 · Financials

0 Cr2000 Cr4000 Cr6000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDARevenue growth YoY

Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.9% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.

02 · Earnings Per Share (EPS)

0255075100₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

010203040₹-500%0%500%1000%12 Nov 2009 Nov 2111 Nov 2204 Aug 2308 Feb 2406 Nov 2410 Nov 2505 Aug 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr₹0×0.25×0.5×0.75×1×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2500 Cr5000 Cr7500 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

0 Cr250 Cr500 Cr750 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,889.69 Cr₹3,340.99 Cr₹3,742.64 Cr₹4,208.71 Cr₹4,648.10 Cr₹5,452.86 Cr
EBITDA₹1,024.54 Cr₹1,044.98 Cr₹881.89 Cr₹1,256.54 Cr₹1,354.00 Cr₹1,566.90 Cr
₹654.00 Cr₹712.68 Cr₹587.98 Cr₹816.17 Cr₹920.39 Cr₹1,056.00 Cr
Diluted EPS₹50.06₹54.97₹45.89₹64.77₹73.53₹84.51

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,778.72 Cr₹4,055.58 Cr₹4,582.00 Cr₹4,530.00 Cr₹4,904.00 Cr₹6,037.00 Cr
₹31.36 Cr₹25.03 Cr₹35.63 Cr₹35.28 Cr₹47.42 Cr₹260.17 Cr
Stockholders' equity₹2,995.63 Cr₹3,264.34 Cr₹3,388.00 Cr₹3,567.00 Cr₹3,790.00 Cr₹4,527.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹576.31 Cr₹562.04 Cr₹792.00 Cr₹785.00 Cr₹1,157.00 Cr₹529.00 Cr
Investing cash flow₹-282.38 Cr₹-74.10 Cr₹-559.60 Cr₹65.39 Cr₹-376.52 Cr₹-428.92 Cr
₹-318.29 Cr₹-460.04 Cr₹-108.00 Cr₹-1,051.00 Cr₹-733.00 Cr₹-168.00 Cr
Capital expenditure₹-171.61 Cr₹-148.84 Cr₹-174.00 Cr₹-152.00 Cr₹-318.00 Cr₹-365.00 Cr
End cash position₹177.51 Cr₹206.36 Cr₹329.83 Cr₹129.49 Cr₹175.12 Cr₹107.47 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Dec 21(2Q)Mar 22–Sep 22(3Q)Dec 22–Mar 23(2Q)Apr 23–Mar 24(5Q)Jun 24Sep 24–Jun 25(4Q)Sep 25–Mar 26(3Q)Jun 26
Promoter70.34%70.48%66.11%66.21%66.27%66.26%66.25%63.48%
Public29.66%29.52%33.89%33.79%33.73%33.74%33.75%36.52%
Employee trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.48 L Cr₹1,837.337.05.3613.7%0.06+11.9%+11.4%
Divi's Laboratories Limited₹2.47 L Cr₹9,37583.314.7715.3%0.00+12.3%+53.4%
Torrent Pharmaceuticals Limited₹1.83 L Cr₹4,87576.921.8225.8%1.79+21.5%+37.4%
Apollo Hospitals Enterprise Limited₹1.26 L Cr₹8,944.560.413.3020.5%0.90+15.7%+13.9%
Lenskart Solutions Limited₹1.18 L Cr₹707.2179.913.485.6%0.35+35.4%—
Zydus Lifesciences Limited₹1.13 L Cr₹1,16025.34.1818.6%0.46+18.4%+10.7%
Cipla Limited₹1.10 L Cr₹1,376.332.53.1911.3%0.02+2.1%-11.8%
Laurus Labs Limited₹1.05 L Cr₹1,95496.419.8616.8%0.48+22.0%+111.6%
Max Healthcare Institute Limited₹1.01 L Cr₹1,049.369.89.3913.4%0.32+19.0%-10.6%
Dr. Reddy's Laboratories Limited₹97,876.16 Cr₹1,18529.62.6011.4%0.21+3.2%-10.4%
Manipal Health Enterprises Limited₹97,364.22 Cr₹738.95146.611.567.8%1.53+18.0%—
Ajanta Pharma Limited₹43,846.87 Cr₹3,500.538.69.6923.3%0.06+17.9%+36.7%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Annual reports

Show all 28

Concall transcripts

Show all 12

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

Index membership

32 indices

Nifty MidSmall Healthcare· 2.3%Nifty Pharma· 1.5%NIFTY Midcap150 Quality 50· 1.1%Nifty500 Healthcare· 1.0%BSE Healthcare· 1.0%Nifty500 Multicap Momentum Quality 50· 0.9%Nifty Total Market Momentum Quality 50· 0.9%Nifty Midcap150 Momentum 50· 0.8%Nifty MidSmallcap400 Momentum Quality 100· 0.6%BSE 150 MidCap Index· 0.4%Nifty Midcap 150· 0.4%Nifty500 Shariah· 0.3%

NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.

AJANTPHARM

Ajanta Pharma Share Price rises 2.04%: valuation, sector

Univest · 12 days ago

AJANTPHARM

Pharma sector stocks today, September 1: Divi’s Laboratories falls 2.88%, Ajanta Pharma down 2.69%, Torrent Pharma declines 2.53%

Business Upturn · 18 days ago